{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:30Z","timestamp":1789469130413,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07226-3","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:34:48Z","timestamp":1786109688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Durable CNS remission with elranatamab and intrathecal therapy in relapsed\/refractory multiple myeloma"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-6000","authenticated-orcid":false,"given":"Sinan","family":"Mersin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6m\u00fcr G\u00f6kmen","family":"Sevindik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"3","key":"7226_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4103\/ijc.IJC_560_20","volume":"62","author":"K Jain","year":"2025","unstructured":"Jain K et al (2025) Central nervous system involvement in multiple myeloma: experience from a tertiary cancer center and review of literature. Indian J Cancer 62(3):416\u2013422","journal-title":"Indian J Cancer"},{"issue":"6","key":"7226_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/ajh.24351","volume":"91","author":"A Jurczyszyn","year":"2016","unstructured":"Jurczyszyn A et al (2016) Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol 91(6):575\u2013580","journal-title":"Am J Hematol"},{"issue":"4","key":"7226_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/bjh.12414","volume":"162","author":"CI Chen","year":"2013","unstructured":"Chen CI et al (2013) Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol 162(4):483\u2013488","journal-title":"Br J Haematol"},{"issue":"6","key":"7226_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura I (2022) Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol 115(6):762\u2013777","journal-title":"Int J Hematol"},{"issue":"3","key":"7226_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-019-0191-y","volume":"9","author":"A Lakshman","year":"2019","unstructured":"Lakshman A et al (2019) Natural history of multiple myeloma with de novo del(17p). Blood Cancer J 9(3):32","journal-title":"Blood Cancer J"},{"issue":"7","key":"7226_CR6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","volume":"105","author":"AE Philip","year":"2020","unstructured":"Philip AE et al (2020) Multiple myeloma with central nervous system relapse. Haematologica 105(7):1780\u20131790","journal-title":"Haematologica"},{"issue":"4","key":"7226_CR7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/biomedicines11041225","volume":"11","author":"A Tyczy\u0144ska","year":"2023","unstructured":"Tyczy\u0144ska A, Turski M, Zarzycka E, Zaucha JM (2023) Isolated progression of multiple myeloma into the extramedullary plasmacytoma of dura mater: a case report and review of the literature. Biomedicines 11(4):1225","journal-title":"Biomedicines"},{"issue":"4","key":"7226_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/ccr3.1451","volume":"6","author":"E Elhassadi","year":"2018","unstructured":"Elhassadi E et al (2018) Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and daratumumab. Clin Case Rep 6(4):723\u2013728","journal-title":"Clin Case Rep"},{"issue":"6","key":"7226_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2643-3230.BCD-24-0124","volume":"5","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk NWCJ et al (2024) T cell-redirecting bispecific antibodies in multiple myeloma: optimal dosing schedule and duration of treatment. Blood Cancer Discov 5(6):388\u2013399","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"7226_CR10","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267","journal-title":"Nat Med"},{"issue":"5","key":"7226_CR11","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1111\/bjh.70108","volume":"207","author":"A Noveihed","year":"2025","unstructured":"Noveihed A, Al Hadidi S, Mohan M, Shah MR (2025) Bispecific antibody therapy in CNS myeloma: early evidence from a multicentre cohort. Br J Haematol 207(5):2161\u20132166","journal-title":"Br J Haematol"},{"key":"7226_CR12","doi-asserted-by":"publisher","first-page":"1276295","DOI":"10.3389\/fimmu.2023.1276295","volume":"14","author":"YG Mutlu","year":"2023","unstructured":"Mutlu YG et al (2023) Relapsed refractory multiple myeloma with CNS involvement successfully treated with elranatamab: first reported case. Front Immunol 14:1276295","journal-title":"Front Immunol"},{"issue":"10","key":"7226_CR13","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ et al (2023) Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med 29(10):2570\u20132576","journal-title":"Nat Med"},{"issue":"8","key":"7226_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07226-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07226-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07226-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:46Z","timestamp":1789465366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07226-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":14,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7226"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07226-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required for this single-patient case report in accordance with the institutional policy of Mersin University Faculty of Medicine.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent to participate was obtained from the patient\u2019s legal representative.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for the publication of clinical details and accompanying images was obtained from the patient\u2019s legal representative. The authors affirm that the patient\u2019s legal representative provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      and\n                      \n                      .","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"408"}}